<DOC>
	<DOC>NCT01011452</DOC>
	<brief_summary>Patients presenting to hospital with an acute asthma exacerbation severe enough to require admission would receive full standard treatment according to British Thoracic Society guidelines in addition they would be offered the opportunity to take part in the study which would requite them to take a capsule of either montelukast or placebo.</brief_summary>
	<brief_title>Acute Montelukast in Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Acute Asthma exacerbation requiring hospitalisation Smoking history greater than or equal to 10 pack years Presenting PEFR greater than or equal to 75% predicted / best Failure to demonstrate greater than or equal to 15% variability in PEFR or FEV during the study Any significant and active pulmonary pathology other than asthma Pregnancy or breastfeeding Intended pregnancy or inability to take adequate precautions against conception Patient already on Montelukast Patient already on Phenobarbitone Patient already on Rifampicin Patient already on Phenytoin Chronic airflow limitation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Acute Asthma Exacerbation</keyword>
	<keyword>Montelukast</keyword>
	<keyword>Management of acute asthma exacerbation</keyword>
</DOC>